Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany

References

• World Health Organization (WHO). Influenza (Seasonal) 2018. Available from: https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).
   Google Scholar
• Robert Koch Institut (RKI). Report on the epidemiology of influenza in Germany - 2018/2019. Berlin, Germany; 2019.
   Google Scholar
• Sellers SA, Hagan RS, Hayden FG, et al. The hidden burden of influenza: a review of the extra-pulmonary complications of influenza infection. Influenza Other Respir Viruses. 2017;11(5):372–393.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). People at high risk for flu complications. Available from: https://www.cdc.gov/flu/highrisk/index.htm.
   Google Scholar
• Robert Koch Institut (RKI). Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute – 2017/2018. Berlin, Germany; 2018.
   Google Scholar
• Harding AT, Heaton NS. Efforts to improve the seasonal influenza vaccine. Vaccines (Basel). 2018;6(2):19.
   PubMed Web of Science ®Google Scholar
• Rajaram S, Boikos C, Gelone DK, et al. Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing. Ther Adv Vaccines Immunother. 2020;8:2515135520908121.
   Google Scholar
• Wu NC, Zost SJ, Thompson AJ, et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 2017;13(10):e1006682.
   PubMed Web of Science ®Google Scholar
• Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A. 2017;114(47):12578–12583.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Cell-based flu vaccines. Available from: https://www.cdc.gov/flu/prevent/cell-based.htm.
   Google Scholar
• European Medicines Agency (EMA). Flucelvax Tetra, summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/flucelvax-tetra-epar-product-information_en.pdf.
   Google Scholar
• Seqirus A CSL company. First cell-based quadrivalent influenza vaccine approved for use in Europe. Available from: https://www.seqirus.com/news/first-cell-based-quadrivalent-influenza-vaccine-approved-in-europe.
   Google Scholar
• Calabro GE, Boccalini S, Del Riccio M, et al. Valutazione di health technology assessment (HTA) del vaccino antinfluenzale quadrivalente da coltura cellulare: FLUCELVAX TETR [Health technology assessment (HTA) evaluation of quadrivalent cell culture flu vaccine: FLUCELVAX TETR]. Ital J Public Health. 2019;8(5):113–143.
   Google Scholar
• Nguyen VH, Nasiri M, Mould-Quevedo J, et al. Cost-effectiveness of a cell culture-based quadrivalent influenza vaccine in the adult population of the United Kingdom. Presented at: 29th National Immunisation Conference for Health Care Workers, London, UK. 2018.
   Google Scholar
• Nguyen VH, Hilsky Y, Mould-Quevedo J. The epidemiological and economic impact of a cell-based quadrivalent influenza vaccine in an adult population in the US: a dynamic modelling approach. Research Square. 2020. DOI:https://doi.org/10.21203/rs.3.rs-27872/v1
   Google Scholar
• Ruiz-Aragón J, Gani R, Márquez S, et al. Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain. Hum Vaccin Immunother. 2020;16(9):2238–2244.
   Web of Science ®Google Scholar
• Eichner M, Schwehm M, Hain J, et al. 4Flu – an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. BMC Infect Dis. 2014;14:365.
   PubMed Web of Science ®Google Scholar
• Haas W. Influenza: Prävention, Diagnostik, Therapie und öffentliche Gesundheit. Munich (Germany): Elsevier GmbH; 2009.
   Google Scholar
• Dolk C, Eichner M, Welte R, et al. Cost-utility of quadrivalent versus trivalent influenza vaccine in Germany, using an individual-based dynamic transmission model. Pharmacoeconomics. 2016;34(12):1299–1308. PubMed PMID: 27647004; PubMed Central PMCID: PMCPMC5110585 this study (GSK Study Identifier: HO-14-14994) and was involved in all stages of the study, including analysis of the data. GlaxoSmithKline Biologicals SA also covered all costs associated with the development and publication of this manuscript. Conflict of interest AA, RSO and RW are employees of the GSK group of companies. RSO, AA and RW declare restricted shares ownership in the GSK group of companies. ME is a shareholder of Epimos GmbH, which has received funding from the GSK group of companies to complete the work disclosed here as well as consultancy fees from AstraZeneca. MS is a shareholder of ExploSYS GmbH, which has received funding from Epimos GmbH to complete the work disclosed here. BPN’s, LAVB’s and IVV’s companies received consultancy fees from the GSK group of companies to complete the work disclosed here as well as for other work outside this study. MP received grants and honoraria from various pharmaceutical companies, inclusive of those developing, manufacturing and marketing influenza vaccines. CD declares no conflict of interest. eng.
   PubMed Web of Science ®Google Scholar
• STIKO. 2016. Modelling methods for predicting epidemiological and health economic effects of vaccinations – Guidance for analyses to be presented to the German Standing Committee on Vaccination (STIKO) (last updated: 16 March 2016), Berlin.
   Google Scholar
• IQWiG. Institute for quality and efficiency in health care: general methods. Cologne, Germany;2015.
   Google Scholar
• European Medicines Agency (EMA). 2018. The Agency’s Committee for Medicinal Products for Human Use (CHMP): European public assessment report (EPAR). http://www.ema.europa.eu/ema/.
   Google Scholar
• Eichner M, Schwehm M, Eichner L, et al. Direct and indirect effects of influenza vaccination. BMC Infect Dis. 2017;17(1):308.
   PubMed Web of Science ®Google Scholar
• Boikos C, Sylvester GC, Sampalis JS, et al. Effectiveness of the cell culture- and egg-derived, seasonal influenza vaccine during the 2017–2018 Northern Hemisphere Influenza Season. Atlanta (GA): National Adult and Influenza Immunization Summit; 2019.
   Google Scholar
• Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis. 2016;16(8):942–951.
   PubMed Web of Science ®Google Scholar
• Rajaram S, Suphaphiphat P, van Boxmeer J, et al. Retrospective assessment of the antigenic similarity of egg-propagated and cell culture-propagated reference influenza viruses as compared with circulating viruses across influenza seasons 2002–2003 to 2017–2018. IJERPH. 2020;17(15):5423.
   Web of Science ®Google Scholar
• Jefferson T, Di Pietrantonj C, Al-Ansary LA, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2018;2(2):CD004876.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;2(7):CD001269.
   Google Scholar
• Jefferson T, Rivetti A, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2012;2012(8):CD004879.
   Google Scholar
• Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167(7):775–785.
   PubMed Web of Science ®Google Scholar
• Boehme AK, Luna J, Kulick ER, et al. Influenza-like illness as a trigger for ischemic stroke. Ann Clin Transl Neurol. 2018;5(4):456–463.
   PubMed Web of Science ®Google Scholar
• Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(4):345–353.
   PubMed Web of Science ®Google Scholar
• Palm F, Urbanek C, Rose S, et al. Stroke incidence and survival in Ludwigshafen am Rhein, Germany: the Ludwigshafen Stroke Study (LuSSt). Stroke. 2010;41(9):1865–1870.
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14(4):539–545.
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Cates SC, Griffin AD, et al. Cost effectiveness of Zanamivir for the treatment of influenza in a high risk population in Australia. Pharmacoeconomics. 2000;17(6):611–620.
   PubMed Web of Science ®Google Scholar
• Inflation rates. Inflation rates in Germany 2018. Available from: https://www.inflation.eu/inflation-rates/germany/historic-inflation/cpi-inflation-germany-2017.aspx.
   Google Scholar
• Robert Koch Institut (RKI). Influenza surveillance: vaccinnation coverage per region in Germany from the year 2009 onwards. Berlin (Germany): Robert Koch Institute; 2018.
   Google Scholar
• G-DRG-Browser. G-DRG-Browser 2018 2018. Available from: http://www.g-drg.de.
   Google Scholar
• EBM. Uniform rating scale: the uniform standard of evaluation (EBM) is the remuneration system of contract medical or contract psychotherapeutic care in Germany 2018. Available from: https://www.bundesgesundheitsministerium.de/service/begriffe-von-a-z/e/einheitlicher-bewertungsmassstab-ebm.html.
   Google Scholar
• EUROSTAT. Labour costs. https://ec.europa.eu/eurostat/web/labour-market/labour-costs. 2019a.
   Google Scholar
• EUROSTAT. Employment and unemployment. https://ec.europa.eu/eurostat/web/lfs/data/database. 2019b.
   Google Scholar
• Kotseva K, Gerlier L, Sidelnikov E, et al. Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe. Eur J Prev Cardiol. 2019;26(11):1150–1157.
   PubMed Web of Science ®Google Scholar
• Stahmeyer JT, Rossol S, Liersch S, et al. Cost-effectiveness of treating hepatitis C with sofosbuvir/ledipasvir in Germany. PloS One. 2017;12(1):e0169401.
   PubMed Web of Science ®Google Scholar
• JCVI PHE (UK). Joint Committee on Vaccination and Immunisation: Advice on influenza vaccines for 2020/21. London (UK): Department of Health & Social Care, Government of the United Kingdom; 2019.
   Google Scholar
• Bruxvoort KJ, Luo Y, Ackerson B, et al. Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017–2018. Vaccine. 2019;37(39):5807–5811.
   PubMed Web of Science ®Google Scholar